Sanofi (NASDAQ:SNY) Receives $62.67 Consensus Target Price from Analysts

Sanofi (NASDAQ:SNY) has been assigned an average rating of “Hold” from the fourteen analysts that are presently covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $62.6667.

Several analysts have weighed in on SNY shares. TD Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th.

Sanofi Trading Down 0.7%

Shares of SNY opened at $43.63 on Friday. The stock’s fifty day simple moving average is $46.94 and its 200-day simple moving average is $48.28. The firm has a market capitalization of $106.41 billion, a PE ratio of 12.12, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45. Sanofi has a 12-month low of $43.34 and a 12-month high of $59.17. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Flagship Harbor Advisors LLC acquired a new stake in shares of Sanofi during the fourth quarter worth $25,000. Financial Consulate Inc. acquired a new position in Sanofi in the third quarter valued at about $26,000. Measured Wealth Private Client Group LLC bought a new position in Sanofi during the third quarter worth about $29,000. Palisade Asset Management LLC bought a new position in Sanofi during the third quarter worth about $30,000. Finally, First Horizon Corp acquired a new position in shares of Sanofi during the 3rd quarter worth about $33,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.